EP1651189B1 - Nouvelles compositions de metaxalone - Google Patents

Nouvelles compositions de metaxalone Download PDF

Info

Publication number
EP1651189B1
EP1651189B1 EP04776615A EP04776615A EP1651189B1 EP 1651189 B1 EP1651189 B1 EP 1651189B1 EP 04776615 A EP04776615 A EP 04776615A EP 04776615 A EP04776615 A EP 04776615A EP 1651189 B1 EP1651189 B1 EP 1651189B1
Authority
EP
European Patent Office
Prior art keywords
less
metaxalone
agents
nanoparticulate
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04776615A
Other languages
German (de)
English (en)
Other versions
EP1651189A1 (fr
Inventor
John D. Pruitt
Tuula A. Ryde
William H. Bosch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of EP1651189A1 publication Critical patent/EP1651189A1/fr
Application granted granted Critical
Publication of EP1651189B1 publication Critical patent/EP1651189B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to novel compositions of metaxalone, comprising metaxalone particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer that is adsorbed on the surface of the drug particles.
  • Nanoparticulate compositions are particles consisting of a poorly soluble therapeutic or diagnostic agent having associated with the surface thereof a non-crosslinked surface stabilizer.
  • the '684 patent does not describe nanoparticulate compositions metaxalone.
  • Nanoparticulate compositions are also described, for example, in U.S. Patent Nos. 5,298,262 for "use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" 5,302,401 for “Method to Reduce Particle Size Growth During Lyophilization;” 5,318,767 for “X-Ray Contrast Compositions Useful in Medical Imaging;” 5,326,552 for “Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” 5,328,404 for “Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;” 5,336,507 for “Use of Charge Phospholipids to Reduce Nanoparticle Aggregation;” 5,340,564 for “Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;” 5,346,702 for "Use of Non-Ionic Cloud Point Modifiers to
  • Patent Application No. 20020012675 A1 published on January 31, 2002 , for “Controlled Release Nanoparticulate Compositions," and WO 02/098565 for “System and Method for Milling Materials,” describe nanoparticulate active agent compositions. None of these references describe nanoparticulate compositions of metaxalone.
  • Amorphous small particle compositions are described, for example, in U.S. Patent Nos. 4,783,484 for "Particulate Composition and Use Thereof as Antimicrobial Agent;” 4,826,689 for “Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;” 4,997,454 for “Method for Making Uniformly-Sized Particles From Insoluble Compounds;” 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;” and 5,776,496 , for “Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.” These references do not describe nanoparticulate metaxalone.
  • Metaxalone is a skeletal muscle relaxant used to relieve the pain of muscle injuries, spasms, sprains, and strains.
  • the mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber. The drug does not directly relax tense skeletal muscles in man. See The Physician's Desk Reference, 57th Edition, p. 1274 (Thompson PDR, Montvale NJ, 2003 ). Metaxalone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.
  • Metaxalone is a tasteless, odorless, white crystalline powder that melts without decomposition at 121.5 to 123 °C.
  • the compound has the chemical name 5-[(3,4-dimethylphenoxy)methyl]-2-oxazolidinone, and the following chemical structure:
  • the chemical structure of metaxalone is unrelated to that of other skeletal muscle relaxants. See http://www.aanos.org/edctn_msk_disordr.htm.
  • Metaxalone is contraindicated in individuals who have shown hypersensitivity to the drug. Metaxalone is also contraindicated for patients with a known tendency to drug induced, hemolytic, or other anemias. It is contraindicated in patients with significantly impaired renal or hepatic function.
  • metaxalone The most frequent reactions to metaxalone include nausea, vomiting, gastrointestinal upset, drowsiness, dizziness, headache, and nervousness or "irritability.” Other adverse reactions include hypersensitivity reaction, characterized by a light rash with or without pruritus, leukopenia, hemolytic anemia, and jaundice.
  • Metaxalone is marketed under the brand name SKELAXIN ® (Elan Pharmaceuticals, Inc.) in 400 mg and 800 mg tablets.
  • the general dosage for adults and children over 12 years of age is two 400 mg tablets (800 mg) or one 800 mg tablet, three to four times a day.
  • SKELAXIN ® The pharmacokinetics of SKELAXIN ® are provided in New Drug Application No. 13-217/S-036; see http://www.fda.gov/cder/foi/label/2002/13217s0361b1.pdf.
  • a single 400 mg SKELAXIN ® (metaxalone) tablet was administered under both fasted and fed conditions.
  • mean peak plasma concentrations (C max ) of 865.3 ng/mL were achieved within 3.3 +/- 1.2 hours (S.D.) after dosing (T max ).
  • the mean apparent oral clearance (CL/F) of metaxalone was 68 +/- 34 L/h.
  • U.S. Patent No. 6,572,880 for "Methods and Transdermal Compositions for Pain Relief” describes compositions of an amine containing compound having biphasic solubility and an agent which enhances the activity of the amine containing compound, such as metaxalone. The compositions are described as being useful in relieving pain.
  • U.S. Patent No. 6,592,980 for “Method for Producing 5-aryloxymethyl-2-oxazolidinones” teaches a method for making the subject compounds comprising fusing a triglycidyl isocyanurate (TGIC) with an unsubstituted or a mono- or di-sobstituted phenol.
  • TGIC triglycidyl isocyanurate
  • U.S. Patent No. 6,538,142 for “Process for the Preparation of Metaxalone” describes a reaction/reduction process for obtaining the desired compound.
  • U.S. Patent No. 6,562,363 for “Bioadhesive Compositions and Methods for Topical Administration of Active Agents,” describes bioadhesive compositions for topical application to skin or mucous membranes.
  • the compositions comprise an admixture of: (1) at least one PVP polymer; (2) at least one bioadhesive solvent suitable for use with an active agent; and (3) an active agent such as metaxalone.
  • WO 2004/105694 published after the priority date of the present application, discloses pharmaceutical compositions and dosage forms for administration of hydrophobic drugs.
  • the pharmaceutical compositions include a hydrophobic drug, preferably a steroid; a solubilizer, preferably a vitamin E substance; and a surfactant.
  • a synergistic effect between the hydrophobic drug and the vitamin E substance results in improved dispersion of the active agent and the solubilizer.
  • the present invention relates to nanoparticulate compositions comprising metaxalone.
  • the compositions comprise metaxalone and at least one surface stabilizer adsorbed on the surface of the metaxalone particles.
  • the nanoparticulate metaxalone particles have an effective average particle size of less than about 2 microns.
  • Another aspect of the invention relates to the use of such a composition for the preparation of a medicament.
  • compositions comprising such a nanoparticulate metaxalone composition.
  • the pharmaceutical compositions preferably comprise metaxalone, at least one surface stabilizer, and at least one pharmaceutically acceptable carrier, as well as any desired excipients.
  • compositions of the invention are described herein.
  • the invention further discloses a method of making a nanoparticulate metaxalone composition.
  • Such a method comprises contacting metaxalone and at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate metaxalone composition in which the surface stabilizer is adsorbed on the surface of the metaxalone particles.
  • the one or more surface stabilizers can be contacted with metaxalone either before, preferably during, or after size reduction of the metaxalone.
  • the present invention is directed to nanoparticulate compositions comprising metaxalone according to claim 1.
  • the compositions comprise metaxalone and at least one surface stabilizer that is adsorbed on the surface of the drug.
  • the nanoparticulate metaxalone particles have an effective average particle size of less than 2 microns.
  • the current formulations of metaxalone suffer from the following problems: (1) the poor solubility of the drug results in a relatively low bioavailability; (2) dosing must be repeated several times each day; and (3) a wide variety of side effects are associated with the current dosage forms of the drug.
  • the nanoparticulate metaxalone formulations of the invention may offer the following advantages: (1) faster onset of action; (2) a potential decrease in the frequency of dosing; (3) smaller doses of metaxalone required to obtain the same pharmacological effect; (4) increased bioavailability; (5) an increased rate of dissolution; (6) improved performance characteristics for oral, intravenous, subcutaneous, or intramuscular injection, such as higher does loading and smaller tablet or liquid dose volumes; (7) improved pharmacokinetic profiles, such as improved T max , C max , and AUC profiles; (8) substantially similar or bioequivalent pharmacokinetic profiles of the nanoparticulate metaxalone compositions when administered in the fed versus the fasted state; (9) bioadhesive metaxalone formulations, which can coat the gut or the desired site of application and be retained for a period of time, thereby increasing the efficacy of the drug as well as eliminating or decreasing the frequency of dosing;
  • a preferred dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
  • Exemplary solid dosage forms include, but are not limited to, tablets, capsules, sachets, lozenges, powders, pills, or granules.
  • the solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof.
  • a solid dose tablet formulation is preferred.
  • Non-nanoparticulate active agent shall mean an active agent which is solubilized or which has an effective average particle size of greater than about 2 microns. Nanoparticulate active agents as defined herein have an effective average particle size of less than about 2 microns.
  • “Poorly water soluble drugs” as used herein means those having a solubility of less than about 30 mg/ml, preferably less than about 20 mg/ml, preferably less than about 10 mg/ml, or preferably less than about 1 mg/ml. Such drugs tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation.
  • 'stable' includes, but is not limited to, one or more of the following parameters: (1) that the metaxalone particles do not appreciably flocculate or agglomerate due to interparticle attractive forces, or otherwise significantly increase in particle size over time; (2) that the physical structure of the metaxalone particles is not altered over time, such as by conversion from an amorphous phase to crystalline phase; (3) that the metaxalone particles are chemically stable; and/or (4) where the metaxalone has not been subject to a heating step at or above the melting point of the metaxalone in the preparation of the nanoparticles of the invention.
  • 'Therapeutically effective amount' as used herein with respect to a drug dosage shall mean that dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that 'therapeutically effective amount,' administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a 'therapeutically effective amount' by those skilled in the art. It is to be further understood that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
  • peak plasma concentration of the nanoparticulate metaxalone can be obtained (T max ) in less than about 2 hours.
  • peak plasma concentration of the nanoparticulate metaxalone can be obtained in less than about 110 min., less than about 100 min., less than about 90 min., less than about 80 min. less than about 70 min., less than about 60 min., less than about 50 min., less than about 40 min., less than about 30 min., less than about 25 min., less than about 20 min., less than about 15 min., or less than about 10 min.
  • exemplary nanoparticulate metaxalone compositions exhibited a T max of 0.38 hr and 0.40 hr under fed conditions, and 0.37 hr and 0.60 hr under fasted conditions. This was in contrast to the T max of SKELAXIN ® OF 2.19 hrs and 1.19 hrs under fed and fasted conditions, respectively.
  • the recommended total daily dose of SKELAXIN ® is 800 mg administered 3-4 times daily, for a total daily dose of 2400 to 3200 mg/day. See Physicians' Desk Reference, 57th Edition, pp. 1274 (2003 ).
  • the metaxalone compositions of the invention may be administered less frequently and at lower doses in dosage forms such as liquid dispersions, powders, sprays, solid re-dispersable dosage forms, ointments, creams, etc.
  • dosage forms such as liquid dispersions, powders, sprays, solid re-dispersable dosage forms, ointments, creams, etc.
  • Exemplary types of formulations useful in the present invention include, but are not limited to, liquid dispersions, gels, aerosols (pulmonary and nasal), ointments, creams, solid dose forms, etc. of nanoparticulate metaxalone.
  • the therapeutically effective amount of the nanoparticulate metaxalone compositions is 1/6, 1/5, 1 ⁇ 4, 1/3 rd , or 1 ⁇ 2 of the therapeutically effective amount of a non-nanoparticulate metaxalone composition, such as SKELAXIN ® .
  • Such lower doses are preferred as they may decrease or eliminate adverse effects of the drug.
  • such lower doses decrease the cost of the dosage form and may increase patient compliance.
  • the nanoparticulate metaxalone compositions of the invention may preferably exhibit increased bioavailability and require smaller doses as compared to prior non-nanoparticulate metaxalone compositions, such as SKELAXIN ® , administered at the same dose.
  • any drug including metaxalone
  • lower doses of metaxalone which can achieve the same or better therapeutic effects as those observed with larger doses of non-nanoparticulate metaxaione compositions, such as SKELAXIN ® , are desired.
  • Such lower doses may be realized with the nanoparticulate metaxalone compositions of the invention because the nanoparticulate metaxalone compositions may exhibit greater bioavailability as compared to non-nanoparticulate metaxalone formulations, which means that smaller dose of metaxalone are likely required to obtain the desired therapeutic effect.
  • nanoparticulate metaxalone compositions exhibited an increase in AUC of about 859% and about 1153% over the AUC for the non-nanoparticulate metaxalone formulation, SKELAXIN ® .
  • the invention also preferably provides metaxalone compositions having a desirable pharmacokinetic profile when administered to mammalian subjects.
  • the desirable pharmacokinetic profile of the metaxalone compositions preferably includes, but is not limited to: (1) a T max for metaxalone; when assayed in the plasma of a mammalian subject following administration, that is preferably less than the T max for a non-nanoparticulate metaxalone formulation ( e .
  • a C max for metaxalone when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the C max for a non-nanoparticulate metaxalone formulation ( e . g ., SKELAXIN ® ), administered at the same dosage
  • an AUC for metaxalone when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the AUC for a non-nanoparticulate metaxalone formulation ( e . g ., SKELAXIN ® ), administered at the same dosage.
  • the desirable pharmacokinetic profile is the pharmacokinetic profile measured after the initial dose of metaxalone.
  • the compositions can be formulated in any way as described below and as known to those of skill in the art.
  • a preferred metaxalone composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate metaxalone formulation (e . g ., SKELAXIN ® ), administered at the same dosage, a T max not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, not greater than about 10%, or not greater than about 5% of the T max exhibited by the non-nanoparticulate metaxalone formulation.
  • a T max not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, not greater than about 10%, or not greater than about 5% of the T max exhibited by the non-nanoparticulate metaxalone formulation.
  • a preferred metaxalone composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate metaxalone formulation of ( e . g ., SKELAXIN ® ), administered at the same dosage, a C max which is at least about 50%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, or at least about 1900% greater than the C max exhibited by the non-nanoparticulate metaxalone formulation.
  • a C max which is at least about 50%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least
  • a preferred metaxalone composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate metaxalone formulation (e.g., SKELAXIN ® ), administered at the same dosage, an AUC which is at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 750%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC exhibited by the non-nan
  • Any formulation giving the desired pharmacokinetic profile is suitable for administration according to the present methods.
  • Exemplary types of formulations giving such profiles are liquid dispersions, gels, aerosols, ointments, creams, solid dose forms, etc. of nanoparticulate metaxalone.
  • the Pharmacokinetic Profiles of the Nanoparticulate Metaxalone Compositions of the Invention are Preferably not Substantially Affected by the Fed or Fasted State of the Subject Ingesting the Compositions
  • the invention encompasses nanoparticulate metaxalone compositions wherein preferably the pharmacokinetic profile of the metaxalone is not substantially affected by the fed or fasted state of a subject ingesting the composition. This means that there is no substantial difference in the quantity of metaxalone absorbed or the rate of metaxalone absorption when the nanoparticulate metaxalone compositions are administered in the fed versus the fasted state.
  • the nanoparticulate metaxalone compositions of the invention can substantially eliminate the effect of food on the pharmacokinetics of metaxalone.
  • the pharmacokinetic profile of the metaxalone compositions of the invention when administered to a mammal in a fasted state, is bioequivalent to the pharmacokinetic profile of the same metaxalone composition administered at the same dosage, when administered to a mammal in a fed state.
  • "Bioequivalency” is preferably established by a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both C max and AUC under U.S.
  • USFDA Food and Drug Administration
  • EMEA European Medicines Evaluation Agency
  • the difference in AUC ( e . g ., absorption) of the nanoparticulate metaxalone composition of the invention, when administered in the fed versus the fasted state is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
  • the difference in C max of the nanoparticulate metaxalone composition of the invention, when administered in the fed versus the fasted state is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
  • the difference in the T max of the nanoparticulate metaxalone compositions of the invention, when administered in the fed versus the fasted state is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 3%, or essentially no difference.
  • Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food.
  • compositions of the invention redisperse such that the effective average particle size of the redispersed metaxalone particles is less than about 2 microns. This is significant, as if upon administration the nanoparticulate metaxalone particles present in the compositions of the invention did not redisperse to a substantially nanoparticulate particle size, then the dosage form may lose the benefits afforded by formulating metaxalone into a nanoparticulate particle size.
  • nanoparticulate metaxalone compositions benefit from the small particle size of metaxalone; if the nanoparticulate metaxalone particles do not redisperse into the small particle sizes upon administration, then "clumps" or agglomerated metaxalone particles are formed. With the formation of such agglomerated particles, the bioavailability of the dosage form may fall.
  • the nanoparticulate metaxalone compositions of the invention exhibit dramatic redispersion of the metaxalone particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution in a biorelevant aqueous media.
  • biorelevant aqueous media can be any aqueous media that exhibit the desired ionic strength and pH, which form the basis for the biorelevance of the media.
  • the desired pH and ionic strength are those that are representative of physiological conditions found in the human body.
  • Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength.
  • Biorelevant pH is well known in the art.
  • the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5.
  • the pH can range from 4 to 6, and in the colon it can range from 6 to 8.
  • Biorelevant ionic strength is also well known in the art. Fasted state gastric fluid has an ionic strength of about 0.1M while fasted state intestinal fluid has an ionic strength of about 0.14. See e . g ., Lindahl et al., "Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women," Pharm. Res., 14 (4): 497-502 (1997 ).
  • pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs ( i . e ., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc .
  • electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof.
  • electrolyte solutions can be, but are not limited to, about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
  • 0.01 M HCl and/or 0.1 M NaCl are most representative of fasted human physiological conditions, owing to the pH and ionic strength conditions of the proximal gastrointestinal tract.
  • Electrolyte concentrations of 0.001 M HCl, 0.01 M HCl, and 0.1 M HCl correspond to pH 3, pH 2, and pH 1, respectively.
  • a 0.01 M HCl solution simulates typical acidic conditions found in the stomach.
  • a solution of 0.1 M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0.1 M may be employed to simulate fed conditions within the human GI tract.
  • Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength include but are not limited to phosphoric acid/phosphate salts + sodium, potassium and calcium salts of chloride, acetic acid/acetate salts + sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts + sodium, potassium and calcium salts of chloride, and citric acid/citrate salts + sodium, potassium and calcium salts of chloride.
  • the redispersed metaxalone particles of the invention (redispersed in an aqueous, biorelevant, or any other suitable media) have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy,
  • an effective average particle size of less than about 2000 nm it is meant that at least 50% of the metaxalone particles have a particle size of less than the effective average, by weight, i . e ., less than about 2000 nm, 1900 nm, 1800 nm, etc., when measured by the above-noted techniques.
  • at least about 70%, about 90%, about 95%, or about 99% of the metaxalone particles have a particle size of less than the effective average, i . e ., less than about 2000 nm, 1900 nm, 1800 nm, 1700 nm, etc.
  • Redispersibility can be tested using any suitable means known in the art. See e . g ., the example sections of U.S. Patent No. 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate.”
  • Bioadhesive nanoparticulate metaxalone compositions of the invention comprise at least one cationic surface stabilizer, which are described in more detail below.
  • Bioadhesive formulations of metaxalone exhibit exceptional bioadhesion to biological surfaces, such as mucous.
  • bioadhesive nanoparticulate metaxalone compositions the term “bioadhesion” is used to describe the adhesion between the nanoparticulate metaxalone compositions and a biological substrate (i . e ., gastrointestinal mucin, lung tissue, nasal mucosa, etc .). See e . g ., U.S. Patent No. 6,428,814 for "Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers," which is specifically incorporated by reference.
  • bioadhesive metaxalone compositions of the invention are useful in any situation in which it is desirable to apply the compositions to a biological surface.
  • the bioadhesive metaxalone compositions preferably coat the targeted surface in a continuous and uniform film which is invisible to the naked human eye.
  • a bioadhesive nanoparticulate metaxalone composition slows the transit of the composition, and some metaxalone particles would also most likely adhere to tissue other than the mucous cells and therefore give a prolonged exposure to metaxalone, thereby increasing absorption and the bioavailability of the administered dosage.
  • a liquid dosage form of a conventional microcrystalline or non-nanoparticulate metaxalone composition would be expected to be a relatively large volume, highly viscous substance which would not be well accepted by patient populations.
  • viscous solutions can be problematic in parenteral administration because these solutions require a slow syringe push and can stick to tubing.
  • conventional formulations of poorly water-soluble active agents, such as metaxalone tend to be unsafe for intravenous administration techniques, which are used primarily in conjunction with highly water-soluble substances.
  • Liquid dosage forms of the nanoparticulate metaxalone compositions of the invention provide significant advantages over a liquid dosage form of a conventional metaxalone microcrystalline compound.
  • the low viscosity and silky texture of liquid dosage forms of the nanoparticulate metaxalone compositions of the invention result in advantages in both preparation and use. These advantages include, for example: (1) better subject compliance due to the perception of a lighter formulation which is easier to consume and digest; (2) ease of dispensing because one can use a cup or a syringe; (3) potential for formulating a higher concentration of metaxalone resulting in a smaller dosage volume and thus less volume for the subject to consume; and (4) easier overall formulation concerns.
  • Liquid metaxalone dosage forms which are easier to consume are especially important when considering juvenile patients, terminally ill patients, and elderly patients. Viscous or gritty formulations, and those that require a relatively large dosage volume, are not well tolerated by these patient populations. Liquid oral dosage forms can be particularly preferably for patient populations who have difficulty consuming tablets, such as infants and the elderly.
  • the viscosities of liquid dosage forms of nanoparticulate metaxalone according to the invention are preferably less than about 1/200, less than about 1/175, less than about 1/150, less than about 1/125, less than about 1/100, less than about 1/75, less than about 1/50, or less than about 1/25 of a liquid oral dosage form of a non-nanoparticulate metaxalone composition, at about the same concentration per ml of metaxalone.
  • the viscosity of liquid nanoparticulate metaxalone dosage forms of the invention is from about 2000 mPa s to about 1 mPa s, from about 1900 mPa ⁇ s to about 1 mPa ⁇ s, from about 1800 mPa ⁇ s to about 1 mPa ⁇ s, from about 1700 mPa ⁇ s to about 1 mPa ⁇ s, from about 1600 mPa ⁇ s to about 1 mPa ⁇ s, from about 1500 mPa ⁇ s to about 1 mPa ⁇ s, from about 1400 mPa ⁇ s to about 1 mPa ⁇ s, from about 1300 mPa ⁇ s to about 1 mPa ⁇ s, from about 1200 mPa ⁇ s to about 1 mPa ⁇ s, from about 1100 mPa ⁇ s to about 1 mPa ⁇ s, from about 1000 mPa ⁇ s to about 1 mPa ⁇ s, from about 900
  • Viscosity is concentration and temperature dependent. Typically, a higher concentration results in a higher viscosity, while a higher temperature results in a lower viscosity. Viscosity as defined above refers to measurements taken at about 20°C. (The viscosity of water at 20°C is 1 mPa s.) The invention encompasses equivalent viscosities measured at different temperatures.
  • nanoparticulate metaxalone compositions of the invention are not turbid.
  • "Turbid,” as used herein refers to the property of particulate matter that can be seen with the naked eye or that which can be felt as “gritty.”
  • the nanoparticulate metaxalone compositions of the invention, formulated into a liquid dosage form can be poured out of or extracted from a container as easily as water, whereas a liquid dosage form of a non-nanoparticulate or solubilized metaxalone is expected to exhibit notably more "sluggish" characteristics.
  • liquid formulations of this invention can be formulated for dosages in any volume but preferably equivalent or smaller volumes than a liquid dosage form of a non-nanoparticulate metaxalone composition.
  • nanoparticulate metaxalone compositions of the invention can be sterile filtered. This obviates the need for heat sterilization, which can harm or degrade metaxalone, as well as result in crystal growth and particle aggregation.
  • Sterile filtration can be difficult because of the required small particle size of the composition. Filtration is an effective method for sterilizing homogeneous solutions when the membrane filter pore size is less than or equal to about 0.2 microns (200 nm) because a 0.2 micron filter is sufficient to remove essentially all bacteria. Sterile filtration is normally not used to sterilize suspensions of micron-sized metaxalone because the metaxalone particles are too large to pass through the membrane pores.
  • a sterile nanoparticulate metaxalone dosage form is particularly useful in treating immunocompromised patients, infants or juvenile patients, and the elderly, as these patient groups are the most susceptible to infection caused by a non-sterile liquid dosage form.
  • nanoparticulate metaxalone compositions of the invention formulated into a liquid dosage form, can be sterile filtered, and because the compositions can have a very small metaxalone effective average particle size, the compositions are suitable for parenteral administration.
  • a first nanoparticulate metaxalone composition providing a desired pharmacokinetic profile is co-administered, sequentially administered, or combined with at least one other metaxalone composition that generates a desired different pharmacokinetic profile. More than two metaxalone compositions can be co-administered, sequentially administered, or combined. While the first metaxalone composition has a nanoparticulate particle size, the additional one or more metaxalone compositions can be nanoparticulate, solubilized, or have a microparticulate particle size.
  • a first metaxalone composition can have a nanoparticulate particle size, conferring a short T max and typically a higher C max .
  • This first metaxalone composition can be combined, co-administered, or sequentially administered with a second composition comprising: (1) metaxalone having a larger (but still nanoparticulate as defined herein) particle size, and therefore exhibiting slower absorption, a longer T max , and typically a lower C max ; or (2) a microparticulate or solubilized metaxalone composition, exhibiting a longer T max , and typically a lower C max .
  • the second, third, fourth, etc., metaxalone compositions can differ from the first, and from each other, for example: (1) in the effective average particle sizes of metaxalone; or (2) in the dosage of metaxalone.
  • Such a combination composition can reduce the dose frequency required.
  • the metaxalone particles of the second composition have at least one surface stabilizer associated with the surface of the drug particles.
  • the one or more surface stabilizers can be the same as or different from the surface stabilizer(s) present in the first metaxalone composition.
  • the two formulations are combined within a single composition, for example a dual-release composition.
  • the invention encompasses the nanoparticulate metaxalone compositions of the invention formulated or co-administered with one or more non-metaxalone active agents. Methods of using such combination compositions are also encompassed by the invention.
  • the non-metaxalone active agents can be present in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi-amorphous phase, or a mixture thereof.
  • the compound to be administered in combination with a nanoparticulate metaxalone composition of the invention can be formulated separately from the nanoparticulate metaxalone composition or co-formulated with the nanoparticulate metaxalone composition.
  • a nanoparticulate metaxalone composition is co-formulated with a second active agent
  • the second active agent can be formulated in any suitable manner, such as immediate-release, rapid-onset, sustained-release, or dual-release form.
  • Such non-metaxalone active agents can be, for example, a therapeutic agent.
  • a therapeutic agent can be a pharmaceutical agent, including a biologic.
  • the active agent can be selected from a variety of known classes of drugs, including, for example, amino acids, proteins, peptides, nucleotides, anti-obesity drugs, central nervous system stimulants, carotenoids, corticosteroids, elastase inhibitors, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, such as NSAIDs and COX-2 inhibitors, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics,
  • Examples of representative active agents useful in this invention include, but are not limited to, acyclovir, alprazolam, altretamine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin, cisapride, clarithromycin, clonidine, clopidogrel, cyclobenzaprine, cyproheptadine, delavirdine, desmopressin, diltiazem, dipyridamole, dolasetron, enalapril maleate, enalaprilat, famotidine, felodipine, furazolidone, glipizide, irbesartan, ketoconazole, lansoprazole, loratadine, loxapine, mebendazole, mercaptopurine, milrinone lactate, mino
  • nutraceuticals or dietary supplements include, but are not limited to, lutein, folic acid, fatty acids (e . g ., DHA and ARA), fruit and vegetable extracts, vitamin and mineral supplements, phosphatidylserine, lipoic acid, melatonin, glucosamine/chondroitin, Aloe Vera, Guggul, glutamine, amino acids ( e .
  • arginine isoleucine, leucine, lysine, methionine, phenylanine, threonine, tryptophan, and valine
  • green tea lycopene
  • whole foods food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish and marine animal oils, and probiotics.
  • Nutraceuticals and dietary supplements also include bio-engineered foods genetically engineered to have a desired property, also known as "pharmafoods.”
  • nutraceuticals and dietary supplements are disclosed, for example, in Roberts et al., Nutraceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods (American Nutraceutical Association, 2001 ). Dietary supplements and nutraceuticals are also disclosed in Physicians' Desk Reference for Nutritional Supplements, 1st Ed. (2001 ) and The Physicians' Desk Reference for Herbal Medicines, 1st Ed. (2001 ), both of which are also incorporated by reference.
  • a nutraceutical or dietary supplement, also known as a phytochemical or functional food is generally any one of a class of dietary supplements, vitamins, minerals, herbs, or healing foods that have medical or pharmaceutical effects on the body.
  • the nanoparticulate metaxalone composition is combined with at least one analgesic.
  • analgesics include, for example, NSAIDS and COX-2 inhibitors.
  • NSAIDS include, but are not limited to, suitable nonacidic and acidic compounds.
  • suitable nonacidic compounds include, for example, nabumetone, tiaramide, proquazone, bufexamac, flumizole, epirazole, tinoridine, timegadine, and dapsone.
  • Suitable acidic compounds include carboxylic acids and enolic acids.
  • Suitable carboxylic acid NSAIDs include, for example: (1) salicylic acids and esters thereof, such as aspirin, diflunisal, benorylate, and fosfosal; (2) acetic acids, including phenylacetic acids such as diclofenac, alclofenac and fenclofenac; (3) carbo- and heterocyclic acetic acids such as etodolac, indomethacin, sulindac, tolmetin, fentiazac, and tilomisole; (4) propionic acids, such as carprofen, fenbufen, flurbiprofen, ketoprofen, oxaprozin, suprofen, tiaprofenic acid, ibuprofen, naproxen, fenoprofen, indoprofen, pirprofen; and (5) fenamic acids
  • Suitable enolic acid NSAIDs include, for example: (1) pyrazolones such as oxyphenbutazone, phenylbutazone, apazone, and feprazone; and (2) oxicams such as piroxicam, sudoxicam, isoxicam, and tenoxicam.
  • COX-2 inhibitors include, but are not limited to, celecoxib (SC-58635, CELEBREX ® , Pharmacia/Searle & Co.), rofecoxib (MK-966, L-748731, VIOXX ® , Merck & Co.), meloxicam (MOBIC ® , co-marketed by Abbott Laboratories, Chicago, IL, and Boehringer Ingelheim Pharmaceuticals), valdecoxib (BEXTRA ® , G.D. Searle & Co.), parecoxib (G.D.
  • the nanoparticulate metaxalone compositions preferably exhibit an increased rate of dissolution as compared to microcrystalline or non-nanoparticulate forms of metaxalone.
  • the nanoparticulate metaxalone compositions preferably exhibit improved performance characteristics for oral, intravenous, subcutaneous, or intramuscular injection, such as higher dose loading and smaller tablet or liquid dose volumes.
  • the nanoparticulate metaxalone compositions of the invention do not require organic solvents or pH extremes.
  • the invention provides compositions comprising nanoparticulate metaxalone particles and at least one surface stabilizer.
  • the surface stabilizers are preferably associated with the surface of the metaxalone particles.
  • Surface stabilizers useful herein do not chemically react with the metaxalone particles or itself.
  • individual molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
  • the compositions can comprise two or more surface stabilizers.
  • the present invention also includes nanoparticulate metaxalone compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
  • the compositions can be formulated for parenteral injection (e . g ., intravenous, intramuscular, or subcutaneous), oral administration (in solid, liquid, or aerosol ( i . e ., pulmonary) form), vaginal, nasal, rectal, ocular, local (powders, creams, ointments or drops), buccal, intracisternal, intraperitoneal, topical administration, and the like.
  • metaxalone Derivatives of metaxalone are also encompassed by the term “metaxalone.”
  • Metaxalone is a skeletal muscle relaxant used to relieve the pain of muscle injuries, spasms, sprains, and strains.
  • the mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber. The drug does not directly relax tense skeletal muscles in man. See The Physician's Desk Reference, 57th Edition, p. 1274 (Thompson PDR, Montvale NJ, 2003 ).
  • Metaxalone can be in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi-amorphous phase, or a mixtures thereof.
  • the choice of a surface stabilizer for metaxalone is non-trivial and required extensive experimentation to realize a desirable formulation. Accordingly, the present invention is directed to the surprising discovery that metaxalone nanoparticulate compositions can be made.
  • Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Surface stabilizers include nonionic, cationic, zwitterionic, and ionic surfactants.
  • hydroxypropyl methylcellulose hydroxypropylcellulose
  • polyvinylpyrrolidone sodium lauryl sulfate, dioctylsulfosuccinate
  • gelatin casein
  • lecithin (phosphatides) dextran
  • gum acacia cholesterol
  • tragacanth stearic acid
  • benzalkonium chloride calcium stearate
  • glycerol monostearate cetostearyl alcohol
  • cetomacrogol emulsifying wax sorbitan esters
  • polyoxyethylene alkyl ethers e .
  • macrogol ethers such as cetomacrogol 1000
  • polyoxyethylene castor oil derivatives polyoxyethylene sorbitan fatty acid esters
  • polyoxyethylene sorbitan fatty acid esters e . g ., the commercially available Tweens ® such as e . g ., Tween 20 ® and Tween 80 ® (ICI Speciality Chemicals)
  • polyethylene glycols e .
  • Pluronics F68 ® and F108 ® which are block copolymers of ethylene oxide and propylene oxide
  • poloxamines e . g ., Tetronic 908 ® , also known as Poloxamine 908 ® , which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); Tetronic 1508 ® (T-1508) (BASF Wyandotte Corporation), Tritons X-200 ® , which is an alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-110 ® , which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin-lOG ® or Surfactant
  • bioadhesive formulations of nanoparticulate metaxalone can be prepared by selecting one or more cationic surface stabilizers that impart bioadhesive properties to the resultant composition.
  • Useful cationic surface stabilizers are described below.
  • cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, 1,2 Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Amino(Polyethylene Glycol)2000] (sodium salt) (also known as DPPE-PEG(2000)
  • cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C 12-15 dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride or bromide, N-
  • Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994 ); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991 ); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990 ).
  • Nonpolymeric cationic surface stabilizers are any nonpolymeric compound, such as benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR 1 R 2 R 3 R 4 (+) .
  • benzalkonium chloride a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound,
  • Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbento
  • the surface stabilizers are commercially available and/or can be prepared by techniques known in the art.
  • Preferred surface stabilizers include, but are not limited to, polyvinylpyrrolidone (PVP), docusate sodium (DOSS), and lysozyme. Particularly preferred is a combination of PVP and DOSS.
  • An example of a preferred composition is 35% metaxalone, 8.75% polyvinylpyrrolidone, and 0.35% DOSS.
  • compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
  • excipients are known in the art.
  • filling agents are lactose monohydrate, lactose anhydrous, and various starches
  • binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel ® PH101 and Avicel ® PH102, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCC TM ).
  • Suitable lubricants including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil ® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
  • flavoring agents are Magnasweet ® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
  • preservatives examples include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
  • Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
  • examples of diluents include microcrystalline cellulose, such as Avicel ® PH101 and Avicel ® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose ® DCL21; dibasic calcium phosphate such as Emcompress ® ; mannitol; starch; sorbitol; sucrose; and glucose.
  • Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof.
  • effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate.
  • Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
  • Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.
  • sodium bicarbonate component of the effervescent couple may be present.
  • particle size is determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation.
  • compositions of the invention comprise metaxalone nanoparticles which have an effective average particle size of less than about 2000 nm ( i . e ., 2 microns), less than about 1900 nm, less than less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 140 nm, less than about 130 nm, less than about 120 nm, less than about 110 nm, less than about 100 nm, less than
  • an effective average particle size of less than about 2000 nm it is meant that at least 50% of the nanoparticulate metaxalone particles have a weight average particle size of less than about 2000 nm, when measured by the above-noted techniques. In other embodiments of the invention, at least about 70%, at least about 90%, at least about 95%, or at least about 99% of the nanoparticulate metaxalone particles have a particle size of less than the effective average, by weight, i.e., less than about 2000 nm, less than about 1900 nm, less than less than about 1800 nm, less than about 1700 nm, etc .
  • nanoparticulate metaxalone composition is combined with a microparticulate metaxalone or non-metaxalone active agent composition, then such a composition is either solubilized or has an effective average particle size of greater than about 2 microns.
  • an effective average particle size of greater than about 2 microns it is meant that at least 50% of the microparticulate metaxalone or non-metaxalone active agent particles have a particle size of greater than about 2 microns, by weight, when measured by the above-noted techniques.
  • At least about 70%, at least about 90%, at least about 95%, or at least about 99%, by weight, of the microparticulate metaxalone or non-metaxalone active agent particles have a particle size greater than about 2 microns.
  • the value for D50 of a nanoparticulate metaxalone composition is the particle size below which 50% of the metaxalone particles fall, by weight.
  • D90 and D99 are the particle sizes below which 90% and 99%, respectively, of the metaxalone particles fall, by weight.
  • the relative amounts of metaxalone and one or more surface stabilizers can vary widely.
  • the optimal amount of the individual components can depend, for example, upon the hydrophilic lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer, etc .
  • the concentration of metaxalone can vary from about 99.5% to about 0.001 %, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined dry weight of the metaxalone and at least one surface stabilizer, not including other excipients.
  • the concentration of the at least one surface stabilizer can vary from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5%, by weight, based on the total combined dry weight of the metaxalone and at least one surface stabilizer, not including other excipients.
  • the nanoparticulate metaxalone compositions can be made using, for example, milling, homogenization, or precipitation techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent. Methods of making nanoparticulate compositions are also described in U.S. Patent No. 5,518,187 for "Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,862,999 for "Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,665,331 for "Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers;” U.S. Patent No.
  • the resultant nanoparticulate metaxalone composition can be utilized in solid or liquid dosage formulations, such as controlled release formulations, solid dose fast melt formulations, aerosol formulations, nasal formulations, lyophilized formulations, tablets, capsules, solid lozenge, powders, creams, ointments, etc .
  • Milling metaxalone to obtain a nanoparticulate dispersion comprises dispersing metaxalone particles in a liquid dispersion media in which metaxalone is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of metaxalone to the desired effective average particle size.
  • the dispersion media can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
  • the metaxalone particles can be reduced in size in the presence of at least one surface stabilizer.
  • the metaxalone particles can be contacted with one or more surface stabilizers after attrition.
  • Other compounds, such as a diluent, can be added to the metaxalone/surface stabilizer composition during the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode.
  • Another method of forming the desired nanoparticulate metaxalone composition is by microprecipitation.
  • This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities.
  • Such a method comprises, for example: (1) dissolving metaxalone in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent.
  • the method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means.
  • Such a method comprises dispersing metaxalone particles in a liquid dispersion media in which metaxalone is poorly soluble, followed by subjecting the dispersion to homogenization to reduce the particle size of the metaxalone to the desired effective average particle size.
  • the dispersion media can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
  • the metaxalone particles can be reduced in size in the presence of at least one surface stabilizer.
  • the metaxalone particles can be contacted with one or more surface stabilizers either before or after attrition.
  • Other compounds, such as a diluent, can be added to the metaxalone/surface stabilizer composition either before, during, or after the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode.
  • the method of the invention comprises administering to a subject an effective amount of a composition comprising nanoparticulate metaxalone.
  • the metaxalone compositions of the present invention can be administered to a subject via any conventional means including, but not limited to, orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracisternally, pulmonary, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray.
  • the term "subject” is used to mean an animal, preferably a mammal, including a human or non-human. The terms patient and subject may be used interchangeably.
  • the USFDA has approved indications for musculoskeletal relaxants, such as metaxalone, as adjuncts to rest and physical therapy for relief of acute, painful musculoskeletal problems.
  • musculoskeletal relaxants such as metaxalone
  • An anti-inflammatory drug may be useful when there is considerable tissue damage and edema.
  • severe musculoskeletal strains and sprains, trauma, and cervical or lumbar radiculopathy as a consequence of degenerative osteoarthritis, herniated disk, spondylitis or laminectomy, often cause moderate or severe and more chronic painful skeletal muscle spasm.
  • the principal symptoms include local pain, tenderness on palpation, increased muscle consistency and limitation of motion.
  • skeletal muscle relaxants alone or in combination with an analgesic are frequently prescribed.
  • Results of some studies have suggested that a formulation of a muscle relaxant and an analgesic provides greater benefit in patients with acute musculoskeletal problems than similar doses of an analgesic alone.
  • compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • the nanoparticulate compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
  • Solid dosage forms for oral administration include, but are not limited to, powder aerosols, capsules, tablets, pills, powders, and granules.
  • the active agent is admixed with at least one of the following: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary am
  • Liquid dosage forms for oral administration include pharmaceutically acceptable aerosols, emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
  • Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • oils such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil
  • glycerol tetrahydrofurfuryl alcohol
  • polyethyleneglycols fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • metaxalone can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form.
  • Actual dosage levels of metaxalone in the nanoparticulate compositions of the invention may be varied to obtain an amount of metaxalone that is effective to obtain a desired therapeutic response for a particular composition and method of administration.
  • the selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered metaxalone, the desired duration of treatment, and other factors.
  • Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
  • the purpose of this example was to prepare a nanoparticulate dispersion of metaxalone.
  • a nanoparticulate colloidal dispersion (NCD) of metaxalone comprising a mixture of 25% (w/w) metaxalone (UniChem Laboratories Ltd. (Germany)), 5% (w/w) polyvinylpyrolidine (PVP) (Plasdone ® K29/32; ISP Technologies), and 0.1 % docusate sodium (DOSS) (Cytec Industries, Inc.), was prepared by wet (aqueous) milling the mixture for 1.5 hours under high energy milling conditions in a DYNO®-Mill KDL (Willy A. Bachofen AG, Maschinenfabrik, Basel, Switzerland) equipped with a 150 cc batch chamber and utilizing 500 ⁇ m polymeric attrition media (Dow Chemical Co.).
  • the final mean (weight) metaxalone particle size was 334 nm, with a D50 of 319 nm, a D90 of 479 nm, and a D95 of 540 nm, as measured with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate dispersion of metaxalone.
  • a nanoparticulate colloidal dispersion (NCD) of metaxalone comprising a mixture of 25% (w/w) metaxalone (UniChem Laboratories Ltd. (Germany)), 10% (w/w) PVP (Plasdone ® K29/32; ISP Technologies), and 0.25% DOSS (Cytec Industries, Inc.), was prepared by wet (aqueous) milling the mixture for 6.5 hours under high energy milling conditions in a DYNO®-Mill KDL (Willy A. Bachofen AG, Maschinenfabrik, Basel, Switzerland) equipped with a 300 cc re-circulation chamber and utilizing 500 ⁇ m polymeric attrition media (Dow Chemical Co.).
  • the final mean (weight) metaxalone particle size was 400 nm, with a D50 of 352 nm, a D90 of 628 nm, and a D95 of 768 nm, as measured with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA.
  • the purpose of this example was to prepare a nanoparticulate dispersion of metaxalone.
  • a nanoparticulate colloidal dispersion (NCD) of metaxalone comprising a mixture of 35% (w/w) metaxalone (UniChem Laboratories Ltd. (Germany)), 7% (w/w) PVP (Plasdone ® K29/32; ISP Technologies), and 0.14% DOSS (Cytec Industries, Inc.), was prepared by wet (aqueous) milling the mixture for 8.4 hours under high energy milling conditions in a two liter Netzsch LMZ-2 Mill (Netzsch, Fxton. PA) equipped with a 20 liter re-circulation vessel and utilizing 500 ⁇ m polymeric attrition media (Dow Chemical Co.)
  • the final mean (weight) metaxalone particle size was 370 nm, with a D50 of 348 nm, a D90 of 344 nm, and a D95 of 624 nm, as measured with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate dispersion of metaxalone.
  • a nanoparticulate coiloidal dispersion (NCD) of metaxalone comprising a mixture of 35% (w/w) metaxalone (UniChem Laboratories Ltd. (Germany)), 8.75% (w/w) PVP (Plasdone ® K29/32; ISP Technologies), and 0.35% DOSS (Cytec Industries, Inc.), was prepared by wet (aqueous) milling the mixture for 6.8 hours under high energy milling conditions in a two liter Netzsch LMZ-2 Mill (Netzsch, Exton, PA) equipped with a 20 liter re-circulation vessel and utilizing 500 ⁇ m polymeric attrition media (Dow Chemical Co.).
  • the final mean (weight) metaxalone particle size was 383 nm, with a D50 of 353 nm, a D90 of 572 nm, and a D95 of 668 nm, as measured with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to determine the in vivo pharmacokinetics of nanoparticulate metaxalone compositions.
  • the final mean (weight) metaxalone particle size was 381 nm, with a D50 of 330 nm, a D90 of 614 nm, and a D95 of 766 nm, as measured with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the formulation was diluted with water to 10% (w/w) metaxalone just prior to dosing.
  • the final mean (weight) metaxalone particle size was 139 nm, with a D50 of 134 nm, a D90 of 190 nm, and a D95 of 210 nm, as measured with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the formulation was diluted with water to 10% (w/w) metaxalone just prior to dosing.
  • the third formulation consisted of a 100 mg dose of a 400 mg Skelaxin ® tablet (Elan Pharmaceuticals, Inc.) ( i . e ., one quarter of the tablet).
  • Skelaxin ® tablet Elan Pharmaceuticals, Inc.
  • the gavage tube was flushed with 18 mL of water.
  • the actual weight of each dose was gravimetrically determined by weighing the full dosing syringe, prior to and the empty syringe immediately following dose administration.
  • Four dogs were dosed with a 1 ⁇ 4 tablet given orally. The weight of the tablet was recorded prior to dosing. Ten mL of was given after dosing.
  • Table 3 below provides a summary of the study protocol.
  • TABLE 3 Study Protocol Treatment period Fed vs. fasted n Route of administration Treatment
  • Dose Week 1 Fasted 4 PO Formulation #1 (10% metaxalone) 100 mg 4 PO Formulation #2 (10% metaxalone) 100 mg 4 PO 1 ⁇ 4 Skelaxin® tablet 100 mg Week 2
  • Fed 4 PO Formulation #1 (10% metaxalone) 100 mg 4 PO Formulation #2 (10% metaxalone) 100 mg 4 PO 1 ⁇ 4 Skelaxin® tablet 100 mg Collection of Blood Samples: Blood samples were collected predose, at 10, 20, 30, 45, and 60 minutes, and at 1.5, 2, 4, 8, 12, and 24 hours after oral doses.
  • C max , T max , and AUC data were calculated from an analysis of the blood samples. The data is shown below in Table 4.
  • Table 4 Pharmacokinetic Data Formulation C max (ng/mL) T max (hours) AUC (ng hr/ml) #1, Fasted 2582.7 0.60 2364.1 #1, Fed 2928.5 0.40 1373.8 #2, Fasted 3454.5 0.37 3087.9 #2, Fed 1045.0 0.38 931.2 Skelaxin ® , Fasted 174.9 1.19 246.5 Skelaxin ® , Fed 343.7 2.19 457.0
  • Formulations #1 and #2 had a C max of 2582.7 ng/mL and 3454.5 ng/mL, respectively, in contrast to the C max of 174.9 ng/mL for Skelaxin ® .
  • This translates into an increase in C max of about 1392% for Formulation #1, and about 1875% for Formulation #2, over the microparticulate formulation of metaxalone, Skelaxin ® .
  • Formulations #1 and #2 had a C max of 2928.5 ng/mL and 1045.0 ng/mL, respectively, in contrast to the C max of 343.7 ng/mL for Skelaxin ® . This translates into an increase in C max of about 752% for Formulation #1, and about 204% for Formulation #2, over the microparticulate formulation of metaxalone, Skelaxin ® .
  • Formulations #1 and #2 had an AUC of 2364.1 ng/mL and 3087.9 ng/mL, respectively, in contrast to the AUC of 246.5 ng/mL for Skelaxin ® . This translates into an increase in AUC of about 859% for Formulation #1, and about 1153% for Formulation #2, over the microparticulate formulation of metaxalone, Skelaxin ® .
  • Formulations #1 and #2 Under fed conditions, Formulations #1 and #2 had an AUC of 1373.8 ng/mL and 931.2 ng/mL, respectively, in contrast to the AUC of 457.0 ng/mL for Skelaxin ® . This translates into an increase in AUC of about 201% for Formulation #1, and about 104% for Formulation #2, over the microparticulate formulation of metaxalone, Skelaxin ® .
  • T max results were equally surprising. Under fasted conditions, Formulations #1 and #2 had a T max of 0.60 hours and 0.37 hours, respectively, in contrast to the T max of 1.19 hours for Skelaxin ® . This translates into a decrease in T max of about 50% for Formulation #1, and about 69% for Formulation #2, over the microparticulate formulation of metaxalone, Skelaxin ® .
  • Formulations #1 and #2 had a T max of 0.40 hours and 0.38 hours, respectively, in contrast to the T max of 2.19 hours for Skelaxin ® . This translates into a decrease in T max of about 82% for Formulation #1, and about 83% for Formulation #2, over the microparticulate formulation of metaxalone, Skelaxin ® .
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers Plasdone® S630, which is a random copolymer of vinyl acetate and vinyl pyrrolidone, and DOSS.
  • a mixture of 5% metaxalone, 2% Plasdone® S630, and 0.1% DOSS was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 4 hours, until the mean particle size of the metaxalone particles was 513 nm, with a D90 of 790 nm.
  • the composition had a mean metaxalone particle size of 492 nm and a D90 of 730 nm.
  • the composition had a mean metaxalone particle size of 548 nm and a D90 of 864 nm.
  • the composition had a mean metaxalone particle size of 392 nm and a D90 of 609 nm. Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers Plasdone® S630 and DOSS.
  • a mixture of 5% metaxalone, 1% Plasdone® S630, and 0.05% DOSS was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 2.5 hours, until the mean particle size of the metaxalone particles was 655 nm, with a D90 of 1217 nm. Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers hydroxypropylmethyl cellulose (HPMC) and DOSS.
  • a mixture of 5% metaxalone, 2% HPMC, and 0.1% DOSS was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 3 hours, until the mean particle size of the metaxalone particles was 596 nm, with a D90 of 1171 nm.
  • the composition had a mean metaxalone particle size of 608 nm and a D90 of 1274 nm.
  • the composition had a mean metaxalone particle size of 584 nm and a D90 of 1107 nm.
  • the composition had a mean metaxalone particle size of 556 nm and a D90 of 990 nm. Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers hydroxypropyl cellulose (HPC-SL).
  • HPC-SL surface stabilizers hydroxypropyl cellulose
  • a mixture of 5% metaxalone and 2% HPC-SL was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 3 hours, until the mean particle size of the metaxalone particles was 317 nm, with a D90 of 454 nm.
  • the composition After 1 day at 5°C, the composition had a mean metaxalone particle size of 336 nm and a D90 of 489 nm; after 1 day at 25°C, the composition had a mean metaxalone particle size of 372 nm; and after 1 day at 40°C, the composition had a mean metaxalone particle size of 433 nm.
  • the composition After 1 week at 5°C, the composition had a mean metaxalone particle size of 349 nm and a D90 of 509 nm; after 1 week at 25°C, the composition had a mean metaxalone particle size of 479 nm; and after 1 week at 40°C, the composition had a mean metaxalone particle size of 617 nm.
  • Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers polyvinylpyrrolidone (PVP) and DOSS.
  • PVP polyvinylpyrrolidone
  • a mixture of 5% metaxalone, 2% PVP, and 0.05% DOSS was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 3 hours, until the mean particle size of the metaxalone particles was 363 nm, with a D90 of 550 nm.
  • the composition had a mean metaxalone particle size of 363 nm and a D90 of 529 nm; after 1 day at 25°C, the composition had a mean metaxalone particle size of 440 nm; and after 1 day at 40°C, the composition had a mean metaxalone particle size of 761 nm.
  • the composition After 13 days at 5°C, the composition had a mean metaxalone particle size of 386 nm and a D90 of 569 nm; after 13 days at 25°C, the composition had a mean metaxalone particle size of 581 nm; and after 13 days at 40°C, the composition had a mean metaxalone particle size of 518 nm. Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers PVP and DOSS.
  • a mixture of 20% metaxalone, 8% PVP, and 0.2% DOSS was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 4 hours, until the mean particle size of the metaxalone particles was 386 nm. After 10 days at 5°C, the composition had a mean metaxalone particle size of 415 nm; and after 10 days at 25°C, the composition had a mean metaxalone particle size of 515 nm.
  • the composition After 24 days at 5°C, the composition had a mean metaxalone particle size of 420 nm; and after 24 days at 25°C, the composition had a mean metaxalone particle size of 548 nm. Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers Plasdone® S630 and DOSS.
  • a mixture of 20% metaxalone, 8% Plasdone® S630, and 0.1% DOSS was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 1.5 hours, until the mean particle size of the metaxalone particles was 408 nm. After 4 days at 5°C, the composition had a mean metaxalone particle size of 435 nm; and after 4 days at 25°C, the composition had a mean metaxalone particle size of 508 nm.
  • DynoMill® Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland
  • the composition After 18 days at 5°C, the composition had a mean metaxalone particle size of 440 nm; and after 18 days at 25°C, the composition had a mean metaxalone particle size of 533 nm. Particle size was measured using a with a Horiba LA-910 particle size analyzer , (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizers PVP and DOSS.
  • a mixture of 20% metaxalone, 2% Plasdone® S630, and 0.2% DOSS was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 1.5 hours, until the mean particle size of the metaxalone particles was 425nm. After 4 days at 5°C, the composition had a mean metaxalone particle size of 407 nm; and after 4 days at 25°C, the composition had a mean metaxalone particle size of 550 nm.
  • the composition After 18 days at 5°C, the composition had a mean metaxalone particle size of 419 nm; and after 18 days at 25°C, the composition had a mean metaxalone particle size of 740 nm. Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).
  • the purpose of this example was to prepare a nanoparticulate metaxalone composition utilizing the surface stabilizer HPC-SL.
  • a mixture of 10% metaxalone and 4% HPC-SL was milled in an aqueous environment in a DynoMill® (Type: KDL; Mfg.: Willy Bachofen, Basel, Switzerland) for 180 minutes, until the mean particle size of the metaxalone particles was 358 nm.
  • the composition had a mean metaxalone particle size of 410 nm; after 3 days at 25°C, the composition had a mean metaxalone particle size of 448 nm; and after 3 days at 40°C, the composition had a mean metaxalone particle size of 739 nm.
  • Particle size was measured using a with a Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Claims (26)

  1. Composition comprenant :
    (a) des particules de métaxalone ou d'un sel de celle-ci, dans laquelle les particules de métaxalone présentent une taille moyenne de particules effective inférieure à 2 000 nm ; et
    (b) au moins un stabilisant de surface, dans laquelle le stabilisant de surface est adsorbé sur la surface des particules de métaxalone,
    à condition que la composition ne soit pas composée de 200 mg de succinate de d-alpha-tocophérol ; de 200 mg de Crémophor RH 40 ; de 100 mg de dibéhénate de glycérol (Compritol 888) ; de 80 mg de distéarate de glycérol (Precivol) ; et de 300 mg de métaxalone.
  2. Composition selon la revendication 1, dans laquelle la métaxalone est choisie dans le groupe constitué par une phase cristalline, une phase amorphe, une phase semi-cristalline, une phase semi-amorphe, et les mélanges de celles-ci.
  3. Composition selon la revendication 1 ou la revendication 2, dans laquelle la taille moyenne de particules effective des particules de métaxalone est choisie dans la gamme constituée par des valeurs inférieure à 1 900 nm, inférieure à 1 800 nm, inférieure à 1 700 nm, inférieure à 1 600 nm, inférieure à 1 500 nm, inférieure à 1 400 nm, inférieure à 1 300 nm, inférieure à 1 200 nm, inférieure à 1 100 nm, inférieure à 1 000 nm, inférieure à 900 nm, inférieure à 800 nm, inférieure à 700 nm, inférieure à 600 nm, inférieure à 500 nm, inférieure à 400 nm, inférieure à 300 nm, inférieure à 200 nm, inférieure à 100 nm, inférieure à 75 nm, et inférieure à 50 nm.
  4. Composition selon l'une quelconque des revendications 1 à 3, dans laquelle la composition est formulée :
    (a) pour une administration choisie dans le groupe constitué par une administration orale, pulmonaire, rectale, ophtalmique, colique, parentérale, intracistémale, intra-vaginale, intrapéritonéale, locale, buccale, nasale, et topique ; et/ou
    (b) en une forme pharmaceutique choisie dans le groupe constitué par des dispersions liquides, des suspensions orales, des gels, des aérosols, des pommades, des crèmes, des formulations à libération modifiée, des formulations à fusion rapide, des formulations lyophilisées, des comprimés, des gélules, des formulations à libération retardée, des formulations à libération prolongée, des formulations à libération pulsatile, et des formulations mixtes à libération immédiate et à libération programmée.
  5. Composition selon l'une quelconque des revendications 1 à 4, dans laquelle :
    (a) la métaxalone ou un de ses sels est présent en une quantité choisie dans le groupe des valeurs de 99,5% à 0,001%, de 95% à 0,1%, et de 90% à 0,5%, en poids, par rapport au poids combiné total de la métaxalone ou d'un de ses sels et d'au moins un stabilisant de surface, à l'exclusion d'autres excipients ; et
    (b) le au moins un stabilisant de surface est présent en une quantité choisie dans le groupe des valeurs de 0,5% à 99,999% en poids, de 5,0% à 99,9% en poids, et de 10% à 99,5% en poids, par rapport au poids sec combiné total de la métaxalone ou d'un de ses sels et d'au moins un stabilisant de surface, à l'exclusion d'autres excipients.
  6. Composition selon l'une quelconque des revendications 1 à 5, dans laquelle au moins un stabilisant de surface :
    (a) est choisi dans le groupe constitué par un stabilisant de surface non ionique, un stabilisant de surface anionique, un stabilisant de surface cationique, un stabilisant de surface zwitterionique, et un stabilisant de surface ionique ; et/ou
    (b) est choisi dans le groupe constitué par le chlorure de cétylpyridinium, la gélatine, la caséine, les phosphatides, le dextrane, le glycérol, la gomme arabique, le cholestérol, la gomme adragante, l'acide stéarique, le chlorure de benzalkonium, le stéarate de calcium, le monostéarate de glycérol, l'alcool cétostéarylique, la cire émulsifiante cétomacrogol, les esters de sorbitan, les éthers polyoxyéthylène d'alkyle, les dérivés d'huile de ricin polyoxyéthyléné, les esters d'acides gras et de sorbitan polyoxyéthyléné, les polyéthylèneglycols, le bromure de dodécyltriméthylammonium, les stéarates de polyoxyéthylène, le dioxyde de silicium colloïdal, les phosphates, le dodécylsulfate de sodium, la carboxyméthylcellulose calcique, les hydroxypropylcelluloses, l'hypromellose, la carboxyméthylcellulose sodique, la méthylcellulose, l'hydroxyéthylcellulose, le phtalate d'hypromellose, la cellulose non cristalline, le silicate de magnésium et d'aluminium, la triéthanolamine, l'alcool polyvinylique, la polyvinylpyrrolidone, un polymère de 4-(1,1,3,3-tétraméthylbutyl)-phénol avec l'oxyde d'éthylène et le formaldéhyde, les poloxamères ; les poloxamines, un phospholipide chargé, le dioctylsulfosuccinate, les esters dialkyliques de sulfosuccinate sodique, le laurylsulfate de sodium, les alkylarylpolyéthersulfonates, les mélanges de stéarate de saccharose et de distéarate de saccharose, le p-isononylphénoxypoly-(glycidol), le décanoyl-N-méthylglucamide ; le n-décyl-β-D-glucopyranoside ; le n-décyl-β-D-maltopyranoside ; le n-dodécyl-β-D-glucopyranoside ; le n-dodécyl-β-D-maltoside ; l'heptanoyl-N-méthylglucamide ; le n-heptyl-β-D-glucopyranoside ; le n-heptyl-β-D-thioglucoside ; le n-hexyl-β-D-glucopyranoside ; le nonanoyl-N-méthylglucamide ; le n-nonyl-β-D-glucopyranoside ; l'octanoyl-N-méthylglucamide ; le n-octyl-β-D-glucopyranoside ; l'octyl-β-D-thioglucopyranoside ; le lysozyme, le PEG-phospholipide, le PEG-cholestérol, un dérivé de PEG-cholestérol, le PEG-vitamine A, les copolymères statistiques d'acétate de vinyle et de vinylpyrrolidone, les polymères cationiques, les biopolymères cationiques, les polysaccharides cationiques, les celluloses cationiques, les alginates cationiques, les composés non polymères cationiques, les phospholipides cationiques, les lipides cationiques, le poly(méthacrylate de méthyle), le bromure de triméthylammonium, les composés sulfonium, le diméthylsulfate de méthacrylate de polyvinylpyrrolidone-2-diméthylaminoéthyle, le bromure d'hexadécyltriméthylammonium, les composés phosphonium, les composés ammonium quaternaire, le bromure de benzyl-di(2-chloroéthyl)éthylammonium, le chlorure de coprah-triméthylammonium, le bromure de coprah-triméthylammonium, le chlorure de coprahméthyldihydroxyéthylammonium, le bromure de coprahméthyldihydroxyéthylammonium, le chlorure de décyltriéthylammonium, le chlorure de décyldiméthylhydroxyéthylammonium, le chlorure et bromure de décyldiméthylhydroxyéthylammonium, le chlorure d'alkyl(en C12 à C15)-diméthylhydroxyéthylammonium, le bromure d'alkyl(en C12 à C15)-diméthylhydroxyéthylammonium, le chlorure de coprah-diméthyl-hydroxyéthylammonium, le bromure de coprah-diméthyl-hydroxyéthylammonium, le méthylsulfate de myristyltriméthylammonium, le chlorure de lauryldiméthyl-benzylammonium, le bromure de lauryldiméthyl-benzylammonium, le chlorure de lauryldiméthyl-(éthénoxy)4-ammonium, le bromure de lauryldiméthyl-(éthénoxy)4-ammonium, le chlorure de N-alkyl(en C12 à C18)-diméthylbenzylammonium, le chlorure de N-alkyl(en C14 à C18)-diméthylbenzylammonium, le chlorure de N-tétradécylidméthylbenzylammonium monohydraté, le chlorure de diméthyldidécylammonium, le chlorure de N-alkyl(en C12 à C14)-diméthyl-1-napthylméthylammonium, l'halogénure de triméthylammonium, les sels d'alkyltriméthylammonium, les sels de dialkyldiméthylammonium, le chlorure de lauryltriméthylammonium, le sel d'alkylamidoalkyldialkylammonium éthoxylé, un sel de trialkylammonium éthoxylé, le chlorure de dialkylbenzène-dialkylammonium, le chlorure de N-didécyldiméthylammonium, le chlorure de N-tétradécyldiméthylbenzylammonium monohydraté, le chlorure de N-alkyl(en C12 à C14)-diméthyl-1-naphtylméthylammonium, le chlorure de dodécyldiméthylbenzylammonium, le chlorure de dialkylbenzènealkylammonium, le chlorure de lauryltriméthylammonium, le chlorure d'alkylbenzylméthylammonium, le bromure d'alkylbenzyldiméthylammonium, les bromures d'alkyl(en C12)-triméthylammonium, les bromures d'alkyl(en C15)-triméthylammonium, les bromures d'alkyl(en C17)-triméthylammonium, le chlorure de dodécylbenzyltriéthylammonium, le poly(chlorure de diallyldiméthylammonium) (DADMAC), les chlorures de diméthylammonium, les halogénures d'alkyldiméthylammonium, le chlorure de tricétylméthylammonium, le bromure de décyltriméthylammonium, le bromure de dodécyltriéthylammonium, le bromure de tétradécyltriméthylammonium, le chlorure de méthyltrioctylammonium, POLYQUAT 10™, le bromure de tétrabutylammonium, le bromure de benzyltriméthylammonium, les esters de choline, le chlorure de benzalkonium, les composés du chlorure de stéaralkonium, le bromure de cétylpyridinium, le chlorure de cétylpyridinium, les halogénures de polyoxyéthylalkylamines quaternisées, MIRAPOL™, ALKAQUAT™, les sels d'alkylpyridinium ; les amines, les sels d'amines, les oxydes d'amines, les sels d'imidazolinium, les acrylamides quaternaires protonés, les polymères quaternaires méthylés, et la gomme guar cationique.
  7. Composition selon la revendication 6, dans laquelle la composition est un bio-adhésif.
  8. Composition selon l'une quelconque des revendications 1 à 7, comprenant au moins un stabilisant de surface primaire et au moins un stabilisant de surface secondaire.
  9. Composition selon l'une quelconque des revendications 1 à 8, comprenant, en tant que stabilisant de surface, la polyvinylpyrrolidone, le docusate de sodium, le lysozyme, ou une combinaison de ceux-ci.
  10. Composition selon l'une quelconque des revendications 1 à 9, comprenant en outre au moins une composition de métaxalone supplémentaire ayant une taille moyenne de particules effective qui est différente de la taille moyenne de particules effective de la composition de métaxalone selon la revendication 1.
  11. Composition selon l'une quelconque des revendications 1 à 10, comprenant en outre un ou plusieurs principes actifs non-métaxalone.
  12. Composition selon la revendication 11, dans laquelle :
    (a) ledit un ou plusieurs principe actif non-métaxalone supplémentaire est choisi dans le groupe constitué par les acides aminés, les protéines, les peptides, les nucléotides, les médicaments destinés au traitement de l'obésité, les stimulants du système nerveux central, les caroténoïdes, les corticostéroïdes, les inhibiteurs de l'élastase, les antifongiques, les agents de thérapie oncologique, les anti-émétiques, les analgésiques, les agents cardio-vasculaires, les agents anti-inflammatoires, les vermifuges, les agents anti-arythmiques, les antibiotiques, les anticoagulants, les antidépresseurs, les agents antidiabétiques, les anti-épileptiques, les antihistaminiques, les agents antihypertenseurs, les agents antimuscariniques, les agents antimycobactériens, les agents antinéoplasiques, les immunosuppresseurs, les agents antithyroïdiens, les agents antiviraux, les anxiolytiques, les sédatifs, les astringents, les agents de blocage du récepteur alpha-adrénergique, les agents de blocage du bêta-adrénocepteur, les produits sanguins, les substituts sanguins, les agents inotropes cardiaques, les milieux de contraste, les corticostéroïdes, les antitussifs, les agents diagnostiques, les agents d'imagerie diagnostique, les diurétiques, les dopaminergiques, les hémostatiques, les agents immunologiques, les agents de régulation du métabolisme des lipides, les myorelaxants, les agents parasympathomimétiques, la calcitonine parathyroïde, les biphosphonates parathyroïdes, les prostaglandines, les produits pharmaceutiques radiologiques, les hormones sexuelles, les agents anti-allergiques, les stimulants, les anorexigènes, les sympathomimétiques, les agents thyroïdiens, les vasodilatateurs, les xanthines, l'acyclovir, l'alprazolam, l'altrétamine, l'amiloride, l'amiodarone, le mésylate de benztropine, le bupropion, la cabergoline, le candesartan, la cérivastatine, la chlorpromazine, la ciprofloxacine, le cisapride, la clarithromycine, la clonidine, le clopidogrel, la cyclobenzaprine, la cyproheptadine, la délavirdine, la desmopressine, le diltiazem, le dipyridamole, le dolasétron, le maléate d'énalapril, l'énalaprilate, la famotidine, la félodipine, la furazolidone, le glipizide, l'irbesartan, le kétoconazole, le lansoprazole, la loratadine, la loxapine, le mébendazole, la mercaptopurine, le lactate de milrinone, la minocycline, la mitoxantrone, le mésylate de nelfinavir, la nimodipine, la norfloxacine, l'olanzapine, l'oméprazole, le penciclovir, le pimozide, le tacolimus, le quazepam, le raloxifenc, la rifabutine, la rifampine, la risperidone, le rizatriptan, le saquinavir, la sertraline, le sildénafil, l'acétyl-sulfisoxazole, le témazépam, le thiabendazole, la thioguanine, le trandolapril, le triamtérène, le trimétrexate, la troglitazone, la trovafloxacine, le vérapamil, le sulfate de vinblastine, le mycophénolate, l'atovaquone, l'atovaquone, le proguanil, la ceftazidime, la céfuroxime, l'étoposide, la terbinafine, le thalidomide, le fluconazole, l'amsacrine, la dacarbazine, le téniposide, l'acétylsalicylate, un AINS, et un inhibiteur de COX-2 ; et/ou
    (b) ledit un ou plusieurs principe actif non-métaxalone supplémentaire est un AINS choisi dans le groupe constitué par la nabumétone, le tiaramide, la proquazone, le buféxamac, le flumizole, l'épirazole, la tinoridine, la timégadine, la dapsone, l'aspirine, le diflunisal, le benorylate, le fosfosal, le diclofénac, l'alclofénac, le fénclofénac, l'étodolac, l'indométhacine, le sulindac, la tolmétine, le fentiazac, le tilomisole, le carprofène, le fenbufène, le flurbiprofène, le kétoprofène, l'oxaprozine, le suprofène, l'acide tiaprofénique, l'ibuprofène, le naproxène, le fénoprofène, l'indoprofène, le pirprofène, l'acide flufénamique, l'acide méfénamiqie, l'acide méclofenamique, l'acide niflumique, l'oxyphénbutazone, la phénylbutazone, l'apazone, le féprazone, le piroxicam, le sudoxicam, l'isoxicam, et le ténoxicam ; et/ou
    (c) ledit un ou plusieurs principe actif non-métaxalone supplémentaire est un inhibiteur de COX-2 choisi dans le groupe constitué par le célécoxib, le rofécoxib, le méloxicam, le valdécoxib, le parécoxib, l'étoricoxib, SC-236, NS-398, SC-58125, SC-57666, SC-558, SC-560, l'étodolac, DFU, le monteleukast, L-745337, L-761066, L-761000, L-748780, DUP-697, PGV 20229, l'iguratimod, BF 389, PD 136005, PD 142893, PD 145065, PD 138387, le flurbiprofène, le nimésulide, le nabumétone, le flosulide, le piroxicam, le diclofénac, le lumiracoxib, D 1367, la diflumidone, JTE-522, FK-3311, FK 867, FR 115068, GR 253035, RWJ 63556, RWJ 20485, ZK 38997, S 2474, CL 1004, RS 57067, RS 104897 RS 104894, SC 41930, le pranlukast, et SB 209670, l'heptinylsulfure, et FR 140423.
  13. Composition selon l'une quelconque des revendications 1 à 12, dans laquelle :
    (a) lors de l'administration à un mammifère, les particules de métaxalone sont redispersées si bien que les particules ont une taille moyenne de particules effective choisie dans le groupe des valeurs inférieure à environ 2 micromètres, inférieure à environ 1 900 nm, inférieure à environ 1 800 nm, inférieure à environ 1 700 nm, inférieure à environ 1 600 nm, inférieure à environ 1 500 nm, inférieure à environ 1 400 nm, inférieure à environ 1 300 nm, inférieure à environ 1 200 nm, inférieure à environ 1 100 nm, inférieure à environ 1 000 nm, inférieure à environ 900 nm, inférieure à environ 800 nm, inférieure à environ 700 nm, inférieure à environ 600 nm, inférieure à environ 500 nm, inférieure à environ 400 nm, inférieure à environ 300 nm, inférieure à environ 250 nm, inférieure à environ 200 nm, inférieure à environ 150 nm, inférieure à environ 100 nm, inférieure à environ 75 nm, et inférieure à environ 50 nm ; et/ou
    (b) la composition est redispersée dans un milieu à visée biologique si bien que les particules ont une taille moyenne de particules effective choisie dans le groupe des valeurs inférieure à 2 micromètres, inférieure à environ 1 900 nm, inférieure à environ 1 800 nm, inférieure à environ 1 700 nm, inférieure à environ 1 600 nm, inférieure à environ 1 500 nm, inférieure à environ 1 400 nm, inférieure à environ 1 300 nm, inférieure à environ 1 200 nm, inférieure à environ 1 100 nm, inférieure à environ 1 000 nm, inférieure à environ 900 nm, inférieure à environ 800 nm, inférieure à environ 700 nm, inférieure à environ 600 nm, inférieure à environ 500 nm, inférieure à environ 400 nm, inférieure à environ 300 nm, inférieure à environ 250 nm, inférieure à environ 200 nm, inférieure à environ 150 nm, inférieure à environ 100 nm, inférieure à environ 75 nm, et inférieure à environ 50 nm.
  14. Composition selon la revendication 13, dans laquelle le milieu à visée biologique est choisi dans le groupe constitué par l'eau, les solutions électrolytiques aqueuses, les solutions aqueuses d'un sel, les solutions aqueuses d'un acide, les solutions aqueuses d'une base, et leurs combinaisons.
  15. Composition selon l'une quelconque des revendications 1 à 14, dans laquelle :
    (a) la valeur Tmax de la métaxalone, lorsque celle-ci est dosée dans le plasma d'un sujet mammifère à la suite d'une administration, est inférieure à la valeur Tmax d'une formulation de métaxalone non-nanoparticulaire, administrée avec le même dosage ; et/ou
    (b) la valeur Tmax est choisie dans le groupe constitué par les valeurs non supérieure à environ 90%, non supérieure à environ 80%, non supérieure à environ 70%, non supérieure à environ 60%, non supérieure à environ 50%, non supérieure à environ 30%, non supérieure à environ 25%, non supérieure à environ 20%, non supérieure à environ 15%, non supérieure à environ 10%, et non supérieure à environ 5% de la valeur Tmax présentée par une formulation de métaxalone non-nanoparticulaire, administrée avec le même dosage.
  16. Composition selon l'une quelconque des revendications 1 à 15, dans laquelle :
    (a) la valeur Cmax de la métaxalone, lorsque celle-ci est dosée dans le plasma d'un sujet mammifère à la suite d'une administration, est supérieure à la valeur Cmax d'une formulation de métaxalone non-nanoparticulaire, administrée avec le même dosage ; et/ou
    (b) la valeur Cmax est choisie dans le groupe constitué par les valeurs d'au moins environ 50%, d'au moins environ 100%, d'au moins environ 200%, d'au moins environ 300%, d'au moins environ 400%, d'au moins environ 500%, d'au moins environ 600%, d'au moins environ 700%, d'au moins environ 800%, d'au moins environ 900%, d'au moins environ 1000%, d'au moins environ 1100%, d'au moins environ 1200%, d'au moins environ 1300%, d'au moins environ 1400%, d'au moins environ 1500%, d'au moins environ 1600%, d'au moins environ 1700%, d'au moins environ 1800%, ou d'au moins environ 1900% supérieure à la valeur Cmax présentée par une formulation de métaxalone non-nanoparticulaire, administrée avec le même dosage.
  17. Composition selon l'une quelconque des revendications 1 à 16, dans laquelle :
    (a) l'aire sous la courbe de la métaxalone, lorsque celle-ci est dosée dans le plasma d'un sujet mammifère suivant l'administration, est supérieure à l'aire sous la courbe d'une formulation de métaxalone non-nanoparticulaire, administrée avec le même dosage ; et/ou
    (b) l'aire sous la courbe est choisie dans le groupe constitué par les valeurs d'au moins environ 25%, d'au moins environ 50%, d'au moins environ 75%, d'au moins environ 100%, d'au moins environ 125%, d'au moins environ 150%, d'au moins environ 175%, d'au moins environ 200%, d'au moins environ 225%, d'au moins environ 250%, d'au moins environ 275%, d'au moins environ 300%, d'au moins environ 350%, d'au moins environ 400%, d'au moins environ 450%, d'au moins environ 500%, d'au moins environ 550%, d'au moins environ 600%, d'au moins environ 750%, d'au moins environ 700%, d'au moins environ 750%, d'au moins environ 800%, d'au moins environ 850%, d'au moins environ 900%, d'au moins environ 950%, d'au moins environ 1000%, d'au moins environ 1050%, d'au moins environ 1100%, d'au moins environ 1150%, ou d'au moins environ 1200% supérieure à l'aire sous la courbe présentée par la formulation de métaxalone non-nanoparticulaire, administrée avec le même dosage.
  18. Composition selon l'une quelconque des revendications 1 à 17 qui ne produit pas de niveaux d'absorption significativement différents lorsqu'elle est administrée dans des conditions d'alimentation par rapport à des conditions de jeun.
  19. Composition selon la revendication 18, dans laquelle la différence d'absorption de la composition de métaxalone de la présente invention, lorsque celle-ci est administrée à l'état alimenté par rapport à l'état à jeun, est choisie dans le groupe constitué par une valeur inférieure à environ 100%, inférieure à environ 90%, inférieure à environ 80%, inférieure à environ 70%, inférieure à environ 60%, inférieure à environ 50%, inférieure à environ 40%, inférieure à environ 30%, inférieure à environ 25%, inférieure à environ 20%, inférieure à environ 15%, inférieure à environ 10%, inférieure à environ 5%, et inférieure à environ 3%.
  20. Composition selon l'une quelconque des revendications 1 à 19, dans laquelle, sur le plan biologique, l'administration de la composition à un être humain dans un état à jeun est équivalente à une administration de la composition à un sujet à l'état alimenté.
  21. Composition selon la revendication 20, dans laquelle "l'équivalence sur le plan biologique" est confirmée par :
    (a) un intervalle de confiance à 90% compris entre 0,80 et 1,25 à la fois pour la valeur Cmax et l'aire sous la courbe, ou
    (b) un intervalle de confiance à 90% compris entre 0,80 et 1,25 pour l'aire sous la courbe et un intervalle de confiance à 90% compris entre 0,70 et 1,43 pour la valeur Cmax.
  22. Composition selon l'une quelconque des revendications 1 à 21, dans laquelle la composition comprend en outre un ou plusieurs excipients, charges acceptables sur le plan pharmaceutique, ou une combinaison de ceux-ci.
  23. Utilisation d'une composition selon l'une quelconque des revendications 1 à 22 pour la préparation d'un médicament.
  24. Utilisation selon la revendication 23, dans laquelle le médicament est utilisé pour des indications thérapeutiques choisies dans le groupe constitué par les indications dans lesquelles on utilise habituellement des relaxants musculosqueléttiques telles que l'ostéoarthrite dégénérative, l'hernie discale, la spondylite, la laminectomie, les élongations musculosquelettiques graves, les entorses musculosquelettiques graves, les traumatismes musculosquelettiques, la radiculopathie cervicale, la radiculopathie lombaire, et une combinaison de celles-ci.
  25. Procédé de fabrication d'une composition de métaxalone selon l'une quelconque des revendications 1 à 22, comprenant la mise en contact de particules de métaxalone ou d'un sel de celle-ci avec au moins un stabilisant de surface pendant une durée et dans des conditions suffisantes pour fournir une composition de métaxalone ayant une taille moyenne de particules effective inférieure à environ 2 000 nm.
  26. Procédé selon la revendication 25, dans lequel ladite mise en contact comprend un broyage, un broyage par voie humide, une homogénéisation, ou une précipitation.
EP04776615A 2003-08-08 2004-07-26 Nouvelles compositions de metaxalone Expired - Lifetime EP1651189B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49344603P 2003-08-08 2003-08-08
PCT/US2004/019108 WO2005016310A1 (fr) 2003-08-08 2004-07-26 Nouvelles compositions de metaxalone

Publications (2)

Publication Number Publication Date
EP1651189A1 EP1651189A1 (fr) 2006-05-03
EP1651189B1 true EP1651189B1 (fr) 2008-12-03

Family

ID=34193183

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04776615A Expired - Lifetime EP1651189B1 (fr) 2003-08-08 2004-07-26 Nouvelles compositions de metaxalone

Country Status (8)

Country Link
US (1) US20050063913A1 (fr)
EP (1) EP1651189B1 (fr)
JP (1) JP2007501839A (fr)
AT (1) ATE415946T1 (fr)
CA (1) CA2534924A1 (fr)
DE (1) DE602004018150D1 (fr)
ES (1) ES2318330T3 (fr)
WO (1) WO2005016310A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4613275B2 (ja) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
PT1471887E (pt) * 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
DK2110124T3 (da) * 2004-03-08 2013-10-21 Spireas Spiridon Biotilgængelige faste dosisformer af metaxalon
EP1753429A1 (fr) 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulateurs de récepteurs muscariniques
WO2006018814A2 (fr) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Suspensions liquides orales de métaxalone
WO2006063078A2 (fr) * 2004-12-08 2006-06-15 Elan Corporation, Plc Composition pharmaceutique de topiramate
KR20070112164A (ko) * 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
WO2006110811A1 (fr) 2005-04-12 2006-10-19 Elan Pharma International Limited Formules de nanoparticules de derives de quinazoline
MX2007012763A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de liberacion controlada que comprenden una cefalosporina para el tratamiento de infeccion bacteriana.
BRPI0608771A2 (pt) * 2005-05-10 2010-01-26 Elan Pharma Int Ltd formulações de clopidogrel em nanopartìcula
WO2006132752A1 (fr) * 2005-05-10 2006-12-14 Elan Pharma International Limited Compositions nanoparticulaires a liberation regulee comprenant de la vitamine k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
KR20080047509A (ko) * 2005-05-23 2008-05-29 엘란 파마 인터내셔널 리미티드 혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
CA2612994A1 (fr) 2005-06-08 2006-12-08 Elan Pharma International Limited Compositions a nanoparticules et a liberation controlee comprenant du cefditoren
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
CN101237868A (zh) * 2005-06-13 2008-08-06 伊兰制药国际有限公司 纳米粒氯吡格雷和阿司匹林组合制剂
JP2008543862A (ja) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子アゼルニジピン製剤
WO2007010508A2 (fr) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Compositions de metaxalone a liberation controlee
EP1937217A2 (fr) * 2005-09-13 2008-07-02 Elan Pharma International Limited Formulations nanoparticulaires de tadalafil
EP2279727A3 (fr) 2005-09-15 2011-10-05 Elan Pharma International Limited Formulations nanoparticulaires d'aripiprazole
ES2761812T3 (es) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007060682A1 (fr) * 2005-11-28 2007-05-31 Strides Arcolab Limited Formulations granulaires effervescentes de medicaments antiretroviraux
PT1954241E (pt) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Formulação de zonisamida de libertação sustentada
EP1965795A2 (fr) * 2005-12-29 2008-09-10 Teva Pharmaceutical Industries Ltd. Formulations de metaxalone et procedes de preparation
WO2007074477A2 (fr) * 2005-12-29 2007-07-05 Dabur Pharma Limited Polymorphes de métaxalone
US20070281011A1 (en) 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2054042B8 (fr) 2006-06-30 2020-06-10 iCeutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
CA2657379A1 (fr) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Formulations de sorafenib nanoparticulaire
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
ATE460925T1 (de) 2006-11-09 2010-04-15 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
CA2668885C (fr) * 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Procedes d'administration de medications pour la perte de poids
US20120093928A1 (en) * 2007-08-09 2012-04-19 Ranbaxy Laboratories Limited Oral metaxalone compositions
WO2009042854A1 (fr) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Compositions régulatrices de canaux ioniques et procédés d'utilisation de ces dernières
WO2009085637A1 (fr) * 2007-12-21 2009-07-09 Url Pharma, Inc. Métaxalone amorphe et ses dispersions amorphes
JP2011520779A (ja) * 2008-03-21 2011-07-21 エラン・ファルマ・インターナショナル・リミテッド イマチニブの部位特異的送達のための組成物および使用の方法
CA2725930A1 (fr) * 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procedes pour traiter des pathologies des graisses viscerales
CN103932988A (zh) 2009-04-24 2014-07-23 伊休蒂卡有限公司 吲哚美辛的新剂型
EP2421530B1 (fr) * 2009-04-24 2019-08-21 Iceutica Pty Ltd. Formulation de métaxalone
US20100316725A1 (en) 2009-05-27 2010-12-16 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US8871793B2 (en) 2009-12-23 2014-10-28 Nuformix Limited Metaxalone cocrystals
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
EP2858640B1 (fr) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition à être utilisée dans une méthode de traitement de la surcharge pondérale et de l'obésité dans de patients présentant un risque cardiovasculaire élevé
CN105007898A (zh) 2012-12-19 2015-10-28 卡希夫制药有限责任公司 难溶性药物的过饱和的稳定纳米颗粒
KR20160039608A (ko) * 2013-07-22 2016-04-11 아이슈티카 인코포레이티드 메탁살론 제형
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US11672781B2 (en) 2018-05-07 2023-06-13 Prana Biosciences Inc Metaxalone formulations
JPWO2022102709A1 (fr) * 2020-11-12 2022-05-19
CN115300458B (zh) * 2022-08-08 2023-11-07 锦州奥鸿药业有限责任公司 一种无糖地氯雷他定口服溶液及其制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993767A (en) * 1975-11-18 1976-11-23 A. H. Robins Company, Incorporated Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
EP0179583A1 (fr) * 1984-10-04 1986-04-30 Merck & Co. Inc. Système pour augmenter la vitesse de dissolution dans l'eau et la solubilité de médicaments peu solubles
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
JPS62501630A (ja) * 1984-12-26 1987-07-02 サンシヤイン，エイブラハム 鎮痛、抗炎症および骨格筋弛緩薬組成物
US4722938A (en) * 1984-12-26 1988-02-02 Analgesic Associates Methods for using musculoskeletal relaxants
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993000933A1 (fr) 1991-07-05 1993-01-21 University Of Rochester Particules poreuses non agregees ultra-petites piegant des bulles gazeuses
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
DE4320096C2 (de) * 1993-06-17 1996-03-14 Passavant Werke Biogasreaktor zur anaeroben Behandlung von Abwässern
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) * 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (fr) * 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2000072973A1 (fr) * 1999-06-01 2000-12-07 Elan Pharma International Ltd. Broyeur reduit et procede associe
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6592980B1 (en) * 1999-12-07 2003-07-15 Air Products And Chemicals, Inc. Mesoporous films having reduced dielectric constants
PT1313564E (pt) * 2000-04-26 2010-01-11 Elan Pharma Int Ltd Aparelho para moagem sanitária por via húmida
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1182338B1 (fr) * 2000-08-25 2007-03-21 Honda Giken Kogyo Kabushiki Kaisha Agencement des auxiliaires d'un moteur à combustion interne
WO2002098565A1 (fr) * 2001-06-05 2002-12-12 Elan Pharma International Limited Systeme et procede de broyage de matieres
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
WO2003080024A2 (fr) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Compositions nanoparticulaires d'inhibiteurs de la proteine kinase activee par des mitogenes (map)
US6538142B1 (en) * 2002-04-18 2003-03-25 Farchemia S.R.L. Process for the preparation of metaxalone
WO2004006959A1 (fr) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Compositions pour doses liquides d'agents actifs nanoparticulaires stables
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability

Also Published As

Publication number Publication date
JP2007501839A (ja) 2007-02-01
US20050063913A1 (en) 2005-03-24
ATE415946T1 (de) 2008-12-15
CA2534924A1 (fr) 2005-02-24
DE602004018150D1 (de) 2009-01-15
WO2005016310A1 (fr) 2005-02-24
ES2318330T3 (es) 2009-05-01
EP1651189A1 (fr) 2006-05-03

Similar Documents

Publication Publication Date Title
EP1651189B1 (fr) Nouvelles compositions de metaxalone
US8236352B2 (en) Glipizide compositions
US7879360B2 (en) Nanoparticulate compositions having a peptide as a surface stabilizer
EP1490025B1 (fr) Compositions nanoparticulaires d'inhibiteurs de la proteine kinase activee par des mitogenes (map)
US7998507B2 (en) Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
EP1658053B1 (fr) Nouvelles compositions de base libre de sildenafil
US7390505B2 (en) Nanoparticulate topiramate formulations
EP1553927B1 (fr) Compositions d'agents actifs nanoparticulaires stabilisees sous forme de gel
US20090047209A1 (en) Novel nifedipine compositions
US20070098805A1 (en) Methods of making and using novel griseofulvin compositions
US20070148100A1 (en) Nanoparticulate aripiprazole formulations
US20040258757A1 (en) Liquid dosage compositions of stable nanoparticulate active agents
US20080152585A1 (en) Low viscosity liquid dosage forms
US20090104273A1 (en) Novel nifedipine compositions
EP1684725A1 (fr) Nouvelles compositions de nimesulide
EP1935407A1 (fr) Formules de dosage de liquide à faible viscosité

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20060622

17Q First examination report despatched

Effective date: 20060622

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PRUITT, JOHN, D.

Inventor name: RYDE, TUULA, A.

Inventor name: BOSCH, WILLIAM, H.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELAN PHARMA INTERNATIONAL LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELAN PHARMA INTERNATIONAL LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004018150

Country of ref document: DE

Date of ref document: 20090115

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2318330

Country of ref document: ES

Kind code of ref document: T3

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E005149

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090303

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090303

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090504

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

26N No opposition filed

Effective date: 20090904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081203

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20110725

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20120725

Year of fee payment: 9

Ref country code: GB

Payment date: 20120725

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120726

Year of fee payment: 9

Ref country code: BE

Payment date: 20120725

Year of fee payment: 9

Ref country code: DE

Payment date: 20120727

Year of fee payment: 9

Ref country code: HU

Payment date: 20120803

Year of fee payment: 9

Ref country code: FR

Payment date: 20120830

Year of fee payment: 9

Ref country code: IT

Payment date: 20120823

Year of fee payment: 9

BERE Be: lapsed

Owner name: ELAN PHARMA INTERNATIONAL LIMITED

Effective date: 20130731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130726

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004018150

Country of ref document: DE

Effective date: 20140201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130726

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130727

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130726

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130726

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130727